Helen is passionate about regulatory affairs, particularly navigating the complex frameworks to achieve swift development of promising agents, enabling them to reach patients sooner – especially in the radiopharmaceutical space.

With commitment to advancing the field of radiopharmaceuticals, Helen strives to deliver solutions that improve patient outcomes and quality of life. She has successfully filed and obtained approvals for multiple products in various markets, and established strong relationships with regulatory agencies and key stakeholders.

As Chair of the Regulatory/Quality Working Group at Nuclear Medicine Europe, she collaborates with industry peers and experts to address the regulatory and quality challenges and opportunities in the nuclear medicine sector.

Before joining Eliquent, Helen worked as the Global Head of Regulatory at the radiopharmaceutical company Blue Earth developing diagnostic and therapeutic radiopharmaceuticals, where she worked closely with US FDA and EMA.

Before transitioning to radiopharmaceuticals, Helen worked as a regulatory consultant, partnering with companies of all sizes across various therapeutic areas including neurology and oncology, to devise regulatory strategies to achieve client’s goals.